AR114024A1 - Composición farmacéutica, dosis y tratamiento de la leucemia ph-positiva - Google Patents

Composición farmacéutica, dosis y tratamiento de la leucemia ph-positiva

Info

Publication number
AR114024A1
AR114024A1 ARP180103163A ARP180103163A AR114024A1 AR 114024 A1 AR114024 A1 AR 114024A1 AR P180103163 A ARP180103163 A AR P180103163A AR P180103163 A ARP180103163 A AR P180103163A AR 114024 A1 AR114024 A1 AR 114024A1
Authority
AR
Argentina
Prior art keywords
treatment
pharmaceutical composition
dosage
positive leukemia
leukemia
Prior art date
Application number
ARP180103163A
Other languages
English (en)
Spanish (es)
Inventor
Fedor Nikolaevich Novikov
Germes Grigorievich Chilov
Original Assignee
Llc «Fusion Pharma»
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Llc «Fusion Pharma» filed Critical Llc «Fusion Pharma»
Publication of AR114024A1 publication Critical patent/AR114024A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP180103163A 2017-10-31 2018-10-31 Composición farmacéutica, dosis y tratamiento de la leucemia ph-positiva AR114024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2017137972A RU2664420C1 (ru) 2017-10-31 2017-10-31 ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ДОЗИРОВКА И СПОСОБ ЛЕЧЕНИЯ Ph+ ЛЕЙКЕМИЙ

Publications (1)

Publication Number Publication Date
AR114024A1 true AR114024A1 (es) 2020-07-15

Family

ID=63177283

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103163A AR114024A1 (es) 2017-10-31 2018-10-31 Composición farmacéutica, dosis y tratamiento de la leucemia ph-positiva

Country Status (4)

Country Link
AR (1) AR114024A1 (fr)
EA (1) EA201991811A1 (fr)
RU (1) RU2664420C1 (fr)
WO (1) WO2019088882A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2477723C2 (ru) * 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
RU2652992C2 (ru) * 2016-04-18 2018-05-04 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Новая кристаллическая солевая форма 3-(1,2,4-триазоло[4,3-а]пиридин-3-илэтинил)-4-метил-n-(4-((4-метилпиперазин-1-ил)метил)-3-трифторметилфенил)бензамида для медицинского применения

Also Published As

Publication number Publication date
RU2664420C1 (ru) 2018-08-17
WO2019088882A1 (fr) 2019-05-09
EA201991811A1 (ru) 2019-12-30

Similar Documents

Publication Publication Date Title
CY1119566T1 (el) Αντιϊικες ενωσεις rsv
SA517390583B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2018007704A (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
CL2015002897A1 (es) Inhibidores de bace1
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
CY1123022T1 (el) Σταθερες φαρμακευτικες συνθεσεις που περιεχουν σιταγλιπτινη υπο τη μορφη δισκιων αμεσης απελευθερωσης
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
AR100365A1 (es) Composición acuosa que comprende ibuprofeno y paracetamol en combinación, proceso para fabricarla y dispositivo inyector para administrarla
MY182134A (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and uses thereof
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
PH12018500886A1 (en) Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
TR201717703A2 (tr) Api̇ksaban formülasyonlari
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
WO2016072692A3 (fr) Composition pour prévenir ou traiter la mucosite, comprenant du necrox en tant que principe actif
AR114024A1 (es) Composición farmacéutica, dosis y tratamiento de la leucemia ph-positiva
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof